Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Expands By 1,201.9%

Posted by Jeff Wilder on Feb 26th, 2026

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 5,585 shares, a growth of 1,201.9% from the January 29th total of 429 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 34,541 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 34,541 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company’s shares are sold short.

Matinas Biopharma Stock Down 3.6%

MTNB opened at $0.60 on Thursday. Matinas Biopharma has a twelve month low of $0.47 and a twelve month high of $3.09. The company has a fifty day moving average of $0.65 and a 200-day moving average of $1.19. The stock has a market cap of $3.86 million, a PE ratio of -0.18 and a beta of 1.31.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is currently owned by institutional investors.

About Matinas Biopharma

(Get Free Report)

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.